一次情報の記録
重要提携・ライセンス契約
Amgen and NORD Launch Learning Collaborative for Rare Autoimmune Diseases
Amgen is sponsoring a 14-month pilot Learning Collaborative with NORD's Rare Disease Centers of Excellence. The initiative focuses on improving diagnosis and care pathways for IgG4-RD and Thyroid Eye Disease, with learnings applicable to other rare diseases. It advances the SPAARK alliance goal of reducing time to rare autoimmune disease diagnosis by 50% by 2036.
主要事実
- 提出
- 2026年10月27日 20:30
- イベント
- 提携・ライセンス契約
- 方向
- 中立
- 信頼度
- 出典あり
- パイロットの期間
- 14か月
- 目標削減率
- 2036年までに50%
出典の抜粋
NORD and Amgen Launch Learning Collaborative to Improve Rare Disease Diagnosis and Care NORD and Amgen Launch Learning Collaborative to Improve Rare Disease Diagnosis and Care News provided by National Organization for Rare Disorders (NORD®) Oct 27, 2026, 08:30 ET Share this article Share this article New Initiative Will Bring Together NORD® Rare Disease Centers of Excellence to Address Challenges in Two Rare Autoimmune Diseases and Develop Approaches that Could Benefit Other Rare Disease Communities WASHINGTON , Oct. 27, 2026 /PRNewswire/ -- The National Organization for Rare Disorders (NORD®) today announced a major collaboration with Amgen to launch a Learning Collaborative through NORD's Rare Disease Centers of Excellence Network to reduce the time to diagnosis for rare disease,